• Oxaliplatin in Translational Oncology: Mechanistic Insigh...

  2025-10-01

  This thought-leadership article explores the mechanistic foundations and translational potential of Oxaliplatin, a third-generation platinum-based chemotherapeutic agent. Integrating recent advances in patient-derived tumor assembloid models and strategic guidance for translational researchers, the article highlights how Oxaliplatin’s DNA adduct formation, apoptosis induction, and proven clinical efficacy can be leveraged with cutting-edge preclinical systems to accelerate personalized cancer therapy.

• Oxaliplatin: Platinum-Based Chemotherapeutic in Advanced ...

  2025-09-30

  Oxaliplatin stands out as a platinum-based chemotherapeutic agent optimized for cutting-edge tumor assembloid and preclinical xenograft research. Its robust DNA adduct formation and apoptosis-inducing capabilities unlock new insights in metastatic colorectal cancer therapy and beyond.

• Oxaliplatin in Next-Generation Tumor Microenvironment Mod...

  2025-09-29

  Explore how Oxaliplatin, a platinum-based chemotherapeutic agent, is unlocking new insights into DNA adduct formation and apoptosis induction in advanced tumor microenvironment models. Discover unique strategies for leveraging preclinical assembloids for more predictive metastatic colorectal cancer therapy.

• Oxaliplatin: Mechanisms and Innovations in Cancer Chemoth...

  2025-09-28

  Explore the molecular mechanisms and advanced applications of Oxaliplatin, a leading platinum-based chemotherapeutic agent. Discover how DNA adduct formation and tumor microenvironment modeling are redefining metastatic colorectal cancer therapy.

• A 83-01: Next-Generation ALK-5 Inhibition for Stem Cell a...

  2025-09-27

  Discover how A 83-01, a selective TGF-β type I receptor inhibitor, is redefining stem cell differentiation and organoid development. This in-depth analysis explores unexplored technical insights and advanced applications, setting a new benchmark for research in cellular growth inhibition and EMT.

• Cy3-UTP: Illuminating RNA Trafficking and Quantitative De...

  2025-09-26

  Explore how Cy3-UTP, a photostable fluorescent RNA labeling reagent, enables quantitative, mechanistic studies of RNA trafficking and nanoparticle delivery. Unlock unique strategies for tracking RNA dynamics beyond conventional imaging.

• X-press Tag Peptide: Enabling Precision in Post-Translati...

  2025-09-25

  Discover how X-press Tag Peptide advances protein purification and post-translational modification studies. This in-depth review explores its unique features, solubility, and applications in probing neddylation and mTORC1 signaling, setting it apart from standard protein purification tag peptides.

• L1023 Anti-Cancer Compound Library: Integrative Platforms...

  2025-09-24

  Explore how the L1023 Anti-Cancer Compound Library revolutionizes cancer research with its pathway-driven, cell-permeable compounds for high-throughput screening. Discover new perspectives on mechanism-based target identification and advanced applications in precision oncology.

• PD 0332991 (Palbociclib) HCl: Distinct Mechanisms of Cell...

  2025-09-23

  Explore how PD 0332991 (Palbociclib) HCl, a selective CDK4/6 inhibitor, mediates tumor growth suppression and cell cycle G1 phase arrest in breast cancer and multiple myeloma research. This article uniquely integrates recent insights on apoptosis signaling independent of transcriptional inhibition.

• Various compounds have been designed

  2025-03-03

  

  Various compounds have been designed to inhibit aldose reductase (AR) [12]. These compounds can be classified into two main categories, the first category comprises those containing a carboxylic SUMO Protease cleavage moiety, for example, 3-thiazolidineacetic acid derivative, which has been reporte

• Gliomas and Aldehyde Dehydrogenase Aldehyde dehydrogenases A

  2025-03-03

  

  Gliomas and Aldehyde Dehydrogenase Aldehyde dehydrogenases (ALDHs) are key metabolic enzymes involved in regulation of glycolysis/gluconeogenesis pathways as well as in the detoxification of endogenous and exogenous aldehydes, regulating cell function and homeostasis. ALDHs play important roles in

• Control of retinal vascularization during development and

  2025-03-03

  

  Control of retinal vascularization during development and OIR likely involves close interactions among endothelial cells, neurons and glial procyanidin supplement (microglial and astrocytes) (see Fig. 2). In particular, the interaction between endothelial tip cells and astrocytes plays a critical r

• Silicristin br Conflict of interest statement br Benign pros

  2025-03-03

  

  Conflict of interest statement Benign prostatic hyperplasia (BPH) is a highly complex process characterized by an increased number of epithelial and stromal Silicristin in the transition zone. , , Autopsy studies by McNeal detail the evolution of histological changes within these 2 cellular c

• br Conclusion br Conflicts of interest

  2025-03-03

  

  Conclusion Conflicts of interest Introduction RNA interference is a specific post-transcriptional gene silencing mechanism within a cell via the transfection of microRNAs (miRNA), exogenous small interfering RNAs (siRNA) or small hairpin RNAs (shRNA) [1–3]. Transfection of shRNA can be done

• The present study showed for the first time that hirsutine

  2025-03-03

  

  The present study showed, for the first time, that hirsutine, hirsuteine, rhynchophylline, isorhynchophylline, corynoxeine, and isocorynoxeine in yokukansan can inhibit the 5-HT3 receptor current. These data indicate that part of the effect of yokukansan against the behavioral and psychological symp

16176 records 2/1079 page Previous Next 12345 下5页 Last page